{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:08:19Z","timestamp":1787875699048,"version":"build-2784847793"},"reference-count":150,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hoc.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:33:19Z","timestamp":1721734399000},"page":"1111-1131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cutaneous B-Cell Lymphomas"],"prefix":"10.1016","volume":"38","author":[{"given":"Jennifer","family":"Villasenor-Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jina","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2024.05.017_bib1","first-page":"228","article-title":"Primary cutaneous follicle centre lymphoma","volume":"227","author":"Willemze","year":"2008","journal-title":"Classification of Tumours of Haematopoietic and Lymphoid Tissues"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.hoc.2024.05.017_bib3","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib4","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib5","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.2005.03.6285","article-title":"Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas","volume":"24","author":"Zinzani","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib6","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2133.2012.11122.x","article-title":"Primary cutaneous B-cell lymphoma in Nottinghamshire U.K.: prognosis of subtypes defined in the WHO-EORTC classification","volume":"167","author":"Bessell","year":"2012","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib9","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1200\/JCO.2006.09.6396","article-title":"Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers","volume":"25","author":"Senff","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaad.2013.04.047","article-title":"Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients","volume":"69","author":"Servitje","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib11","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1080\/10428190802064925","volume":"49","author":"Golling","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib12","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone b-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1111\/bjd.14932","article-title":"Paediatric primary cutaneous marginal zone B-cell lymphoma: does it differ from its adult counterpart?","volume":"176","author":"Amitay-Laish","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib14","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/pde.14811","article-title":"Primary cutaneous lymphomas in children: A prospective study from the Spanish Academy of Dermatology and Venereology (AEDV) Primary Cutaneous Lymphoma Registry","volume":"38","author":"Torre-Castro","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib15","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1177\/12034754221077694","article-title":"Pediatric cutaneous hematologic disorders: cutaneous lymphoma and leukemia cutis-experience of a tertiary-care pediatric institution and review of the literature","volume":"26","author":"Colmant","year":"2022","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib16","doi-asserted-by":"crossref","first-page":"e1000","DOI":"10.1016\/j.clml.2021.07.021","article-title":"Primary cutaneous b-cell lymphomas in children and adolescents: a SEER population-based study","volume":"21","author":"Bomze","year":"2021","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib17","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jdcr.2017.06.024","article-title":"Epidermotropic marginal zone lymphoma: An uncommon cutaneous B-cell lymphoma responsive to rituximab","volume":"3","author":"Magro","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.hoc.2024.05.017_bib18","doi-asserted-by":"crossref","first-page":"152101","DOI":"10.1016\/j.anndiagpath.2022.152101","article-title":"Primary cutaneous blastic marginal zone lymphoma: a comprehensive clinical, light microscopic, phenotypic and cytogenetic appraisal","volume":"63","author":"Magro","year":"2023","journal-title":"Ann Diagn Pathol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/DAD.0000000000000022","article-title":"Clonality assessment of cutaneous B-cell lymphoid proliferations: a comparison of flow cytometry immunophenotyping, molecular studies, and immunohistochemistry\/in situ hybridization and review of the literature","volume":"36","author":"Schafernak","year":"2014","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/10428190500305380","article-title":"Evaluation of B-cell clonality in archival skin biopsy samples of cutaneous B-cell lymphoma by immunoglobulin heavy chain gene polymerase chain reaction","volume":"47","author":"Lukowsky","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib21","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/DAD.0b013e31818118f7","article-title":"Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates","volume":"30","author":"Morales","year":"2008","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib22","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jid.2018.02.015","article-title":"Panel sequencing shows recurrent genetic FAS alterations in primary cutaneous marginal zone lymphoma","volume":"138","author":"Maurus","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/jid.2008.243","article-title":"Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation","volume":"129","author":"Deutsch","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib24","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1365-2133.2009.09576.x","article-title":"Primary cutaneous B-cell lymphoma is associated with somatically hypermutated immunoglobulin variable genes and frequent use of VH1-69 and VH4-59 segments","volume":"162","author":"Perez","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib25","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00000478-200308000-00003","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases","volume":"27","author":"Li","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib26","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.humpath.2006.02.012","article-title":"Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma","volume":"37","author":"Gallardo","year":"2006","journal-title":"Hum Pathol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib27","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1182\/blood-2002-09-2963","article-title":"T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma","volume":"101","author":"Streubel","year":"2003","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/path.1711","article-title":"FISH analysis of MALT lymphoma-specific translocations and aneuploidy in primary cutaneous marginal zone lymphoma","volume":"205","author":"Schreuder","year":"2005","journal-title":"J\u00a0Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib29","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/modpathol.2008.159","article-title":"Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States","volume":"21","author":"Takino","year":"2008","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib30","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/DAD.0b013e31804795a6","article-title":"Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH\/BCL2 and the t(14;18)(q32;q21) IGH\/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma?","volume":"29","author":"Palmedo","year":"2007","journal-title":"Am J Dermatopathol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib31","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.leu.2403644","article-title":"T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma","volume":"19","author":"Streubel","year":"2005","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib32","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1097\/PAS.0b013e3181f72835","article-title":"Cutaneous marginal zone lymphomas have distinctive features and include 2 subsets","volume":"34","author":"Edinger","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib33","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1182\/blood-2008-01-132415","article-title":"The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develops in a T-helper type 2 inflammatory environment","volume":"112","author":"van Maldegem","year":"2008","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib34","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/PAI.0000000000000462","article-title":"IgG4 expression in primary cutaneous marginal zone lymphoma: a multicenter study","volume":"26","author":"De Souza","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib35","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/PAS.0000000000001363","article-title":"Class-switched primary cutaneous marginal zone lymphomas are frequently Igg4-positive and have features distinct from Igm-positive cases","volume":"43","author":"Carlsen","year":"2019","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib36","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/modpathol.2013.106","article-title":"Primary cutaneous marginal zone lymphomas with plasmacytic differentiation show frequent IgG4 expression","volume":"26","author":"Brenner","year":"2013","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib37","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/cup.14111","article-title":"IRTA1 positivity helps identify a MALT-lymphoma-like subset of primary cutaneous marginal zone lymphomas, largely but not exclusively defined by IgM expression","volume":"49","author":"Carlsen","year":"2022","journal-title":"J\u00a0Cutan Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.15183","article-title":"Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype","volume":"177","author":"Wobser","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib39","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0046-8177(00)80233-6","article-title":"Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin","volume":"31","author":"Roggero","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.hoc.2024.05.017_bib40","unstructured":"National Comprehensive Cancer Network\u00ae (NCCN\u00ae) Clinical Practice Guidelines in Oncology. Primary Cutaneous Lymphomas. Version 1.2024 (December 21, 2023)."},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib41","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1182\/blood-2006-10-054601","volume":"110","author":"Kim","year":"2007","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib42","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/hon.2181","article-title":"Role of 18F-FDG-PET\/CT in the management of marginal zone B cell lymphoma","volume":"33","author":"Carrillo-Cruz","year":"2015","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib43","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1634\/theoncologist.2015-0175","article-title":"Primary cutaneous B-cell lymphoma: management and patterns of recurrence at the multimodality cutaneous lymphoma clinic of the Ohio State University","volume":"20","author":"Haverkos","year":"2015","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib44","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1182\/blood-2008-04-152850","article-title":"European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas","volume":"112","author":"Senff","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jaad.2017.07.053","article-title":"Very low-dose versus standard dose radiation therapy for indolent primary cutaneous B-cell lymphomas: A retrospective study","volume":"78","author":"Goyal","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib46","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2133.2010.09798.x","article-title":"Intralesional corticosteroid therapy for primary cutaneous B-cell lymphoma","volume":"163","author":"Perry","year":"2010","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib47","doi-asserted-by":"crossref","DOI":"10.5070\/D3218028432","article-title":"A\u00a0case report of primary cutaneous marginal zone lymphoma treated with intralesional steroids","volume":"21","author":"Kollipara","year":"2015","journal-title":"Dermatol Online J"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib48","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1097-0142(20001015)89:8<1835::AID-CNCR26>3.0.CO;2-H","article-title":"Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma","volume":"89","author":"Heinzerling","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib49","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1365-2133.2005.06659.x","article-title":"Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation","volume":"153","author":"Gellrich","year":"2005","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib50","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jaad.2008.08.005","article-title":"Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab","volume":"59","author":"Morales","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib51","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1093\/annonc\/mdn636","article-title":"Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients","volume":"20","author":"Valencak","year":"2009","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib52","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1365-2133.2006.07523.x","article-title":"Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases","volume":"155","author":"Kerl","year":"2006","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib53","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/archderm.141.9.1139","article-title":"Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases","volume":"141","author":"Hoefnagel","year":"2005","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib54","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/archderm.136.3.374","article-title":"Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma","volume":"136","author":"Heinzerling","year":"2000","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib55","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1600-0609.2006.00720.x","article-title":"Favorable outcome of primary cutaneous marginal zone lymphoma treated with intralesional rituximab","volume":"77","author":"Kyrtsonis","year":"2006","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib56","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1001\/archderm.138.11.1421","article-title":"Topical targretin and intralesional interferon alfa for cutaneous lymphoma of the scalp","volume":"138","author":"Trent","year":"2002","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1080\/10428190500399698","article-title":"Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma","volume":"47","author":"Cozzio","year":"2006","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib58","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1111\/j.1365-2133.2004.06229.x-i1","article-title":"Topical mechlorethamine and clobetasol in multifocal primary cutaneous marginal zone-B cell lymphoma","volume":"154","author":"Bachmeyer","year":"2006","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib59","first-page":"391","article-title":"Topical imiquimod as treatment for different kinds of cutaneous lymphoma","volume":"16","author":"Coors","year":"2006","journal-title":"Eur J Dermatol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib60","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/j.1600-0560.1997.tb01318.x","article-title":"Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma","volume":"24","author":"Cerroni","year":"1997","journal-title":"J\u00a0Cutan Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib61","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/00000478-200009000-00012","article-title":"Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland","volume":"24","author":"Goodlad","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib62","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-200305000-00017","article-title":"Borrelia-Associated Primary Cutaneous MALT Lymphoma in a Nonendemic Region","volume":"27","author":"de la Fouchardiere","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib63","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/pde.14165","article-title":"Primary cutaneous marginal zone lymphoma treated with doxycycline in a pediatric patient","volume":"37","author":"Jothishankar","year":"2020","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00105-009-1766-5","article-title":"[Cutaneous marginal zone lymphoma (SALT) and infection with Borrelia burgdorferi]","volume":"61","author":"F\u00fchler","year":"2010","journal-title":"Hautarzt"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib65","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1634\/theoncologist.2011-0108","article-title":"Prevalence of Borrelia burgdorferi infection in a series of 98 primary cutaneous lymphomas","volume":"16","author":"Ponzoni","year":"2011","journal-title":"Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib66","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1034\/j.1600-0560.2001.281002.x","article-title":"Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States","volume":"28","author":"Wood","year":"2001","journal-title":"J\u00a0Cutan Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib67","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1080\/10428190701618250","article-title":"Clinicopathological features of primary cutaneous B-cell lymphomas from an academic regional hospital in central Italy: no evidence of Borrelia burgdorferi association","volume":"48","author":"Goteri","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib68","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/jdv.18003","article-title":"No evidence of Borrelia in cutaneous infiltrates of B-cell lymphomas with a highly sensitive, semi-nested real-time polymerase chain reaction targeting the 5S-23S intergenic spacer region","volume":"36","author":"Papadopoulou","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib69","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000106580","article-title":"Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report","volume":"215","author":"Monari","year":"2007","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib70","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/bloodadvances.2020002469","article-title":"Genomic landscape of cutaneous follicular lymphomas reveals 2 subgroups with clinically predictive molecular features","volume":"5","author":"Zhou","year":"2021","journal-title":"Blood Adv"},{"issue":"21","key":"10.1016\/j.hoc.2024.05.017_bib71","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib72","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1200\/JCO.2002.20.3.647","article-title":"Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features","volume":"20","author":"Mirza","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib73","first-page":"432","article-title":"Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma","volume":"137","author":"Bergman","year":"2001","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib74","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jaad.2010.06.059","article-title":"Clinicopathologic features of early lesions of primary cutaneous follicle center lymphoma, diffuse type: implications for early diagnosis and treatment","volume":"65","author":"Gulia","year":"2011","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2024.05.017_bib75","series-title":"Skin lymphoma : the illustrated guide","author":"Cerroni","year":"2020"},{"issue":"Suppl 1","key":"10.1016\/j.hoc.2024.05.017_bib76","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41379-019-0385-7","article-title":"Navigating the cutaneous B-cell lymphomas: avoiding the rocky shoals","volume":"33","author":"Jaffe","year":"2020","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib77","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood-2004-04-1594","article-title":"Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling","volume":"105","author":"Hoefnagel","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib78","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1200\/JCO.2005.02.0842","article-title":"Array-based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B-cell lymphoma","volume":"24","author":"Dijkman","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib79","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib80","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/00000478-200206000-00006","article-title":"Primary cutaneous follicular lymphoma: a clinicopathologic and molecular study of 16 cases in support of a distinct entity","volume":"26","author":"Goodlad","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib81","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1046\/j.1365-2133.2001.04128.x","article-title":"Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma","volume":"144","author":"Child","year":"2001","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.hoc.2024.05.017_bib82","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.humpath.2020.09.014","article-title":"The molecular landscape and other distinctive features of primary cutaneous follicle center lymphoma","volume":"106","author":"Barasch","year":"2020","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib83","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00428-018-2384-3","article-title":"Concomitant 1p36 deletion and TNFRSF14 mutations in primary cutaneous follicle center lymphoma frequently expressing high levels of EZH2 protein","volume":"473","author":"G\u00e1ng\u00f3","year":"2018","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib84","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.immuni.2019.05.022","article-title":"The HVEM-BTLA Axis Restrains T Cell Help to Germinal Center B Cells and Functions as a Cell-Extrinsic Suppressor in Lymphomagenesis","volume":"51","author":"Mintz","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.hoc.2024.05.017_bib85","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.jid.2016.04.018","article-title":"MYD88 somatic mutation is a diagnostic criterior in primary cutaneous large b-cell lymphoma","volume":"136","author":"Menguy","year":"2016","journal-title":"J\u00a0Invest Dermatol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib87","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaad.2014.01.862","article-title":"Chromosomal anomalies in primary cutaneous follicle center cell lymphoma do not portend a poor prognosis","volume":"70","author":"Abdul-Wahab","year":"2014","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"16","key":"10.1016\/j.hoc.2024.05.017_bib88","doi-asserted-by":"crossref","first-page":"3602","DOI":"10.1200\/JCO.2001.19.16.3602","article-title":"Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study","volume":"19","author":"Grange","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib89","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/bjd.15071","article-title":"Primary cutaneous B-cell lymphoma: systemic spread is rare while cutaneous relapses and secondary malignancies are frequent","volume":"177","author":"Chan","year":"2017","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib90","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood-2005-03-1175","article-title":"Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients","volume":"106","author":"Kodama","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib91","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.jaad.2013.06.011","article-title":"Primary cutaneous B-cell lymphomas: part I. Clinical features, diagnosis, and classification","volume":"69","author":"Su\u00e1rez","year":"2013","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ijrobp.2015.01.008","article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Specht","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib93","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijrobp.2008.06.1918","article-title":"Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas","volume":"74","author":"Neelis","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib94","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2015.1040012","article-title":"Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy","volume":"57","author":"Akhtari","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib95","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.12484","article-title":"Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas","volume":"169","author":"Brandenburg","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.hoc.2024.05.017_bib96","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00651","article-title":"Primary cutaneous b-cell lymphomas: an update","volume":"10","author":"Vitiello","year":"2020","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib97","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archderm.143.9.1144","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases","volume":"143","author":"Grange","year":"2007","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib98","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1053\/hupa.2002.126881","article-title":"Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity","volume":"33","author":"Paulli","year":"2002","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib99","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/archderm.1996.03890350042008","article-title":"Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group","volume":"132","author":"Vermeer","year":"1996","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib100","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ijrobp.2013.07.019","article-title":"Treatment and outcomes in patients with primary cutaneous b-cell lymphoma: the BC cancer agency experience","volume":"87","author":"Hamilton","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib101","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/cam4.865","article-title":"Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers","volume":"5","author":"Lucioni","year":"2016","journal-title":"Cancer Med"},{"key":"10.1016\/j.hoc.2024.05.017_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2021.01.006","article-title":"Double expressor and double\/triple hit status among primary cutaneous diffuse large B-cell lymphoma: a comparison between leg type and not otherwise specified subtypes","volume":"111","author":"Lucioni","year":"2021","journal-title":"Hum Pathol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib103","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1097\/PAS.0000000000001132","article-title":"High incidence and clinical significance of MYC rearrangements in primary cutaneous diffuse large b-cell lymphoma, leg type","volume":"42","author":"Schrader","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib104","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/ajd.12705","article-title":"MYC protein expression is associated with poor prognosis in cutaneous diffuse large B-cell lymphoma","volume":"59","author":"Kim","year":"2018","journal-title":"Australas J Dermatol"},{"issue":"8","key":"10.1016\/j.hoc.2024.05.017_bib105","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/s41379-018-0041-7","article-title":"Double-hit or dual expression of MYC and BCL2 in primary cutaneous large B-cell lymphomas","volume":"31","author":"Menguy","year":"2018","journal-title":"Mod Pathol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib106","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large b-cell lymphoma, leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib107","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1001\/jamadermatol.2014.821","article-title":"High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type","volume":"150","author":"Pham-Ledard","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib108","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1016\/j.jid.2019.05.008","article-title":"Mutations of the b-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large b-cell lymphoma leg type","volume":"139","author":"Ducharme","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib109","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1038\/jid.2008.357","article-title":"Fine-mapping chromosomal loss at 9p21: correlation with prognosis in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"129","author":"Senff","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib110","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large b-cell lymphoma, leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.hoc.2024.05.017_bib111","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib112","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","article-title":"Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001","volume":"107","author":"Morton","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib113","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1524-4725.1984.tb00898.x","article-title":"Skin involvement of malignant B-cell lymphomas","volume":"10","author":"Sterry","year":"1984","journal-title":"J\u00a0Dermatol Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib114","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaad.2011.03.031","article-title":"Primary cutaneous diffuse large B-cell lymphoma, leg type and secondary cutaneous involvement by testicular B-cell lymphoma share identical clinicopathological and immunophenotypical features","volume":"66","author":"Muniesa","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib115","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1001\/jamadermatol.2013.7452","article-title":"Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France","volume":"150","author":"Grange","year":"2014","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.hoc.2024.05.017_bib116","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1200\/JCO.2000.18.10.2152","article-title":"Primary cutaneous B-cell lymphoma: review and current concepts","volume":"18","author":"Pandolfino","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib117","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1200\/JCO.1996.14.2.549","article-title":"Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy","volume":"14","author":"Rijlaarsdam","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib118","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1365-2133.2007.08239.x","volume":"157","author":"Senff","year":"2007","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib119","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hon.2919","article-title":"Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"39","author":"Kraft","year":"2021","journal-title":"Hematol Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib120","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/bjh.16211","article-title":"Rituximab, lenalidomide and pembrolizumab in refractory primary cutaneous diffuse large B-cell lymphoma, leg type","volume":"187","author":"Di Raimondo","year":"2019","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19061758","article-title":"Molecular mechanisms of disease progression in primary cutaneous diffuse large b-cell lymphoma, leg type during ibrutinib therapy","volume":"19","author":"Fox","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib122","doi-asserted-by":"crossref","first-page":"6067","DOI":"10.4081\/rt.2015.6067","article-title":"Excellent outcome of immunomodulation or bruton's tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large b-cell lymphoma, leg type","volume":"7","author":"Gupta","year":"2015","journal-title":"Rare Tumors"},{"key":"10.1016\/j.hoc.2024.05.017_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00002","article-title":"Successful treatment of primary cutaneous diffuse large b-cell lymphoma leg type with single-agent venetoclax","volume":"3","author":"Walter","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib124","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1097\/PAS.0000000000000851","article-title":"Tumor microenvironment and checkpoint molecules in primary cutaneous diffuse large b-cell lymphoma-new therapeutic targets","volume":"41","author":"Mitteldorf","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1365-2133.2007.07954.x","article-title":"Skin manifestations of intravascular lymphoma mimic inflammatory diseases of the skin","volume":"157","author":"R\u00f6glin","year":"2007","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib126","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2141.2004.05177.x","article-title":"Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'","volume":"127","author":"Ferreri","year":"2004","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib127","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.3390\/curroncol29050237","article-title":"Intravascular large b-cell lymphoma: a review with a focus on the prognostic value of skin involvement","volume":"29","author":"Breakell","year":"2022","journal-title":"Curr Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/blood-2006-01-021253","article-title":"Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5","volume":"109","author":"Murase","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2024.05.017_bib129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12883-015-0509-8","article-title":"Neurological presentations of intravascular lymphoma (IVL): meta-analysis of 654 patients","volume":"16","author":"Fonkem","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.hoc.2024.05.017_bib130","doi-asserted-by":"crossref","first-page":"482","DOI":"10.12659\/AJCR.903816","article-title":"Intravascular large b cell lymphoma presenting as fever of unknown origin and diagnosed by random skin biopsies: a case report and literature review","volume":"18","author":"di Fonzo","year":"2017","journal-title":"Am J Case Rep"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib131","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3324\/haematol.10829","article-title":"Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions","volume":"92","author":"Ferreri","year":"2007","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.hoc.2024.05.017_bib132","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0025-6196(11)61097-5","article-title":"Use of random skin biopsy for diagnosis of intravascular large b-cell lymphoma","volume":"82","author":"Asada","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib133","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jaad.2008.03.010","article-title":"The use of blind skin biopsy in the diagnosis of intravascular B-cell lymphoma","volume":"59","author":"Le","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib134","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1182\/blood-2018-11-887570","article-title":"Sensitivity and specificity of incisional random skin biopsy for diagnosis of intravascular large B-cell lymphoma","volume":"133","author":"Matsue","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.jaad.2019.09.015","article-title":"Skin biopsy in the diagnosis of intravascular lymphoma: A retrospective diagnostic accuracy study","volume":"85","author":"Rozenbaum","year":"2021","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.hoc.2024.05.017_bib136","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2016.12.026","article-title":"Usefulness of senile hemangioma biopsy for diagnosis of intravascular large B-cell lymphoma: A report of two cases and a literature review","volume":"373","author":"Sakurai","year":"2017","journal-title":"J\u00a0Neurol Sci"},{"issue":"1","key":"10.1016\/j.hoc.2024.05.017_bib137","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/12034754221130257","article-title":"Recommendations for an approach to random skin biopsy in the diagnosis of intravascular b-cell lymphoma","volume":"27","author":"MacGillivary","year":"2023","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"18","key":"10.1016\/j.hoc.2024.05.017_bib138","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib139","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s004280100398","article-title":"Analysis of the immunoglobulin heavy chain gene variable region of intravascular large B-cell lymphoma","volume":"439","author":"Kanda","year":"2001","journal-title":"Virchows Arch"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib140","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1111\/j.1365-2559.2005.02013.x","article-title":"Detection of t(14;18) translocation in a case of intravascular large B-cell lymphoma: a germinal centre cell origin in a subset of these lymphomas?","volume":"46","author":"Vieites","year":"2005","journal-title":"Histopathology"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib141","doi-asserted-by":"crossref","DOI":"10.1097\/00000421-200204000-00015","article-title":"Chromosomal aberrations in intravascular lymphomatosis","volume":"25","author":"Tsukadaira","year":"2002","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib142","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2008.07338.x","article-title":"The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma","volume":"143","author":"Ferreri","year":"2008","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2024.05.017_bib143","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/s41409-019-0491-7","article-title":"Outcome of patients receiving consolidative autologous peripheral blood stem cell transplantation in the frontline treatment of intravascular large B-cell lymphoma: Adult Lymphoma Working Group of the Japan Society for Hematopoietic Cell Transplantation","volume":"54","author":"Kato","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2024.05.017_bib144","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bmt.2016.339","article-title":"Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience","volume":"52","author":"Meissner","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib145","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/PAS.0b013e3181cf8622","article-title":"EBV positive mucocutaneous ulcer--a study of 26 cases associated with various sources of immunosuppression","volume":"34","author":"Dojcinov","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1016\/j.hoc.2024.05.017_bib146","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/ccr3.287","article-title":"Age-related Epstein\u2013Barr virus-positive mucocutaneous ulcer: a case report","volume":"3","author":"Magalhaes","year":"2015","journal-title":"Clinical Case Reports"},{"issue":"6","key":"10.1016\/j.hoc.2024.05.017_bib147","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.oooo.2015.06.028","article-title":"EBV-positive mucocutaneous ulcer of the oral cavity associated with HIV\/AIDS","volume":"120","author":"Bunn","year":"2015","journal-title":"Oral Surg, Oral Med, Oral Pathol Oral Radiol"},{"issue":"5","key":"10.1016\/j.hoc.2024.05.017_bib148","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12185-011-0943-3","article-title":"Multi-focal EBV-mucocutaneous ulcer heralding late-onset T-cell immunodeficiency in a woman with lupus erythematosus","volume":"94","author":"Au","year":"2011","journal-title":"Int J Hematol"},{"issue":"11","key":"10.1016\/j.hoc.2024.05.017_bib149","doi-asserted-by":"crossref","DOI":"10.1097\/PAS.0000000000000282","article-title":"EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder","volume":"38","author":"Hart","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.hoc.2024.05.017_bib150","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/bmt.2015.245","article-title":"Presentation and management of post-allogeneic transplantation EBV-positive mucocutaneous ulcer","volume":"51","author":"Nelson","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2024.05.017_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22031053","article-title":"Epstein-Barr virus-positive mucocutaneous ulcer: a unique and curious disease entity","volume":"22","author":"Ikeda","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000662?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858824000662?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T20:24:51Z","timestamp":1725049491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858824000662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":150,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0889858824000662"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.017","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cutaneous B-Cell Lymphomas","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}